



PRESS RELEASE

Pähl, October 2012

CPhI 2012: Aenova remains on track for expansion

The Aenova Group, one of the world's leading companies in the pharmaceutical and healthcare industry, is presenting its extensive portfolio of services and its most recent innovations at CPhI in Madrid. Alongside Aenova's comprehensive full-service offering in the field of pharmaceutical development, the focus will also be on its enhanced expertise in multiple-unit pellet systems (MUPS) and the development and manufacturing of effervescent products at its Bad Aibling site.

Aenova will be presenting its comprehensive range of services at CPhI, the world's largest international trade fair for the pharmaceutical industry, from 9 to 11 October in Madrid in hall 3, booth 3D52. The company provides its customers with a wide variety of pharmaceutical development services, such as formulation and process development, analysis and stability testing for raw materials, intermediates and finished products. Its extended portfolio also includes scaling-up tests, product transfers and manufacturing and packaging clinical trial batches.

Against the background of Aenova's additional development expertise, a new large-scale production line for pellets is being planned at the company's FDA-certified plant in Lyons, which has previously concentrated on manufacturing tablets and packaging. A pilot production facility has already been brought into operation. Aenova will be extending its development and production services, in particular in the field of multiple-unit pellet systems (MUPS).

Members of the Aenova Group





Following the increase in the production capacity at the Tittmoning plant last year, the focus is now on the Bad Aibling site, where a highly efficient production line for effervescent products came into operation in June of this year. The new facility brings the annual production capacity of the plant up to 250 million effervescent tablets and the plan is to double this during the course of next year.

About Aenova

With a turnover of around EUR 280 million, the Aenova Group is one of the world's leading companies in the pharmaceutical and healthcare industry. Its high quality standards, innovative technologies and clear focus on the future have made Aenova one of Europe's main providers of development, manufacturing and marketing services for medicines and dietary supplements. Its portfolio consists of solid dosage forms, including soft gelatin capsules, hard capsules, conventional tablets, film-coated tablets, dragées and effervescent tablets. The company's headquarters are located in Pähl near Munich. It has seven production sites in five countries (Germany, Switzerland, France, Romania and the USA) and employs a total of around 1600 people.

For further press information, please contact:

Söllner Communications AG

Dominik Herrmann

Rosenkavalierplatz 5

81925 Munich

Tel.: +49 (0)89 41 94 73 13

Fax: +49 (0)89 41 94 73 26

E-mail: dominik.herrmann@w-soellner.de

Members of the Aenova Group

